Recent “buzzwords” like “tumor-infiltrating lymphocytes,” “checkpoint blockade,” and “PD-1 blockade” suggest that there is a focused shift towards understanding and enhancing the immunotherapeutic approaches for treating KRAS-induced malignancies. The gene discussed is KRAS; the disease is neoplasm.